NA
DRNA

NewEdge Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

NewEdge Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,327
Closed -$273K – 1259
2021
Q2 		$273K Buy
+7,327
New +$225K 0.01% 942

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

NewEdge Advisors's DRNA Position: Q3 2021 in Review

NewEdge Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 7,327 shares — an estimated $273K sold.

NewEdge Advisors first reported a position in DRNA in Q2 2021 and held it in 1 quarter. The position peaked at $273K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • NewEdge Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • NewEdge Advisors sold 7,327 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $273K.
  • NewEdge Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2021 and held it in 1 quarter.
  • NewEdge Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $273K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on NewEdge Advisors's 13F filing for Q3 2021, filed 29 Oct 2021.